Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $170.00

Merck & Co., Inc. (NYSE:MRK) had its target price increased by BMO Capital Markets from $142.00 to $170.00 in a report released on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the stock. BMO Capital Markets’ target price suggests a potential upside of 12.49% from the stock’s current price.

Several other equities research analysts also recently commented on MRK. Weiss Ratings downgraded shares of Merck & Co., Inc. from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, August 11th. Morgan Stanley raised shares of Merck & Co., Inc. from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $116.00 to $179.00 in a research report on Thursday. Jefferies Financial Group lowered shares of Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a report on Wednesday. UBS Group upped their price objective on shares of Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Guggenheim raised their price objective on Merck & Co., Inc. from $145.00 to $146.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Fifteen equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Merck & Co., Inc. has an average rating of “Moderate Buy” and a consensus target price of $142.10.

Merck & Co., Inc. Trading Down 0.7%

NYSE MRK traded down $1.07 on Thursday, reaching $151.13. The company had a trading volume of 7,921,023 shares, compared to its average volume of 10,777,994. Merck & Co., Inc. has a 52 week low of $77.58 and a 52 week high of $153.50. The stock’s 50 day moving average is $126.86 and its 200-day moving average is $120.74. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. The stock has a market cap of $372.86 billion, a price-to-earnings ratio of 120.90, a PEG ratio of 5.83 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The company’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period in the previous year, the company earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities analysts predict that Merck & Co., Inc. will post 2.77 earnings per share for the current year.

Insider Transactions at Merck & Co., Inc.

In other news, EVP David Michael Williams sold 52,847 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the transaction, the executive vice president owned 31,716 shares in the company, valued at $4,084,069.32. This represents a 62.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jennifer Zachary sold 80,315 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the sale, the executive vice president directly owned 45,509 shares of the company’s stock, valued at $6,073,631.14. This represents a 63.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Merck & Co., Inc.

Large investors have recently added to or reduced their stakes in the company. Kingdom Financial Group LLC. acquired a new stake in Merck & Co., Inc. in the 4th quarter valued at approximately $25,000. Prosperity Bancshares Inc acquired a new position in Merck & Co., Inc. during the 4th quarter worth approximately $26,000. Abound Financial LLC bought a new position in shares of Merck & Co., Inc. during the 4th quarter worth approximately $26,000. Graney & King LLC grew its stake in shares of Merck & Co., Inc. by 400.0% during the 2nd quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after acquiring an additional 200 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $31,000. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Landmark cancer-vaccine trial success: Merck and Moderna reported that their personalized mRNA therapy, intismeran, combined with Merck’s Keytruda, met the primary endpoint in a Phase 3 melanoma study. The treatment improved recurrence-free survival and distant metastasis-free survival versus Keytruda alone in high-risk patients. The result could expand Keytruda’s commercial opportunity and create a new growth avenue as its patent expiration approaches later this decade. Reuters trial report
• Positive Sentiment: Analyst upgrades and higher targets: Morgan Stanley upgraded MRK to “overweight” with a $179 price target, while UBS raised its target to $175 and initiated a “buy” rating. The targets imply continued upside and indicate that analysts view the melanoma results as strategically important for Merck’s oncology pipeline. Analyst ratings report
• Positive Sentiment: Potentially broader pipeline value: The first positive late-stage validation of a personalized mRNA cancer vaccine has strengthened expectations that similar Merck-Moderna programs could target additional cancers, supporting longer-term pipeline diversification beyond Keytruda. Reuters cancer-vaccine analysis
• Neutral Sentiment: Mixed Wall Street signals: RBC raised its price target to $150 but maintained a “sector perform” rating, while Jefferies downgraded Merck from “strong buy” to “hold.” This suggests some analysts believe the recent gains already reflect much of the positive news. Analyst ratings report
• Negative Sentiment: Profit-taking and data limitations: Moderna’s shares have retreated after an exceptionally large rally, and Merck has also eased from its highs. Investors are awaiting detailed Phase 3 data and regulatory filings; approval, commercial adoption and the economics of the partnership remain uncertain.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.